The U.S. Food and Drug Administration has cleared another blood test that could help doctors identify whether a patient's memory problems are likely caused by Alzheimer's disease. The new test, called ...

The U.S. Food and Drug Administration has approved a second blood test to improve the detection of Alzheimer’s disease. The “Elecsys pTau181 test” measures pTau181 protein levels in human plasma which ...

A new blood test could speed up diagnosis and treatment for people dealing with early memory or thinking changes. The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to ...

Roche, which currently has investigational Alzheimer’s disease drug trontinemab in phase 3 trials, has secured FDA clearance of its blood-based biomarker test for the condition. The minimally invasive ...

The Eisai- and Biogen-partnered Alzheimer’s disease drug Leqembi has been available to date as an intravenous infusion that takes about an hour. Patients will soon have the option to choose an ...

Eli Lilly and Company LLY announced that the European Commission (EC) has granted marketing authorization to Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD).

Aug 28 (Reuters) - The U.S. Food and Drug Administration said on Thursday it is recommending additional, earlier scans to monitor brain swelling prior to the third infusion for patients with Alzheimer ...

The U.S. Food and Drug Administration (FDA) stated on Thursday that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare ...